Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 28;11(9):2488.
doi: 10.3390/jcm11092488.

Anxiety and Depression in Metabolic-Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk

Abdulrahman Ismaiel  1 , Mihail Spinu  2 , Daniel-Corneliu Leucuta  3 , Stefan-Lucian Popa  1 , Bogdan Augustin Chis  1 , Mihaela Fadgyas Stanculete  4   5 , Dan Mircea Olinic  2   6 , Dan L Dumitrascu  1
Affiliations

Anxiety and Depression in Metabolic-Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk

Abdulrahman Ismaiel et al. J Clin Med. .

Abstract

(1) Background: The relationship between anxiety and depression in metabolic-dysfunction-associated fatty liver disease (MAFLD) and cardiovascular (CV) risk remains uncertain. Therefore, we aimed to assess whether anxiety and depression are associated with increased CV risk in MAFLD. (2) Methods: We conducted a cross-sectional observational study involving 77 subjects (39 MAFLD patients, 38 controls), between January and September 2020. Hepatic steatosis was assessed using a combination of hepatic ultrasonography and SteatoTestTM. CV parameters were evaluated using echocardiography and Doppler ultrasound. Self-reported questionnaires pertaining to symptoms of anxiety and depression were used. Anxiety was evaluated using Lehrer Woolfolk Anxiety Symptom Questionnaire (LWASQ), further divided into somatic, behavioral, and cognitive factors, as well as a global score, and depression using Beck Depression Inventory (BDI). (3) Results: MAFLD patients presented significantly higher BDI scores (p-value 0.009) and LWASQ global scores (p-value 0.045) than controls. LWASQ somatic factor was significantly associated with global longitudinal strain (GLS) in linear analysis (-0.0404, p-value = 0.002), while it lost significance following multivariate analysis (-0.0166, p-value = 0.124). Although group (MAFLD vs. controls) predicted BDI, LWASQ global score, and LWASQ somatic factor in linear regression, they lost significance in multivariate analysis. Moreover, the relationship between interventricular septal wall thickness (IVSWT) and BDI, LWASQ global score, and LWASQ somatic factor was significant in linear analysis, but statistical significance disappeared after multivariate analysis. (4) Conclusions: Although MAFLD patients presented increased anxiety and depression risk in univariate analysis, this association lost significance in multivariate analysis. A significant association between GLS levels and LWASQ somatic factor, in addition to IVSWT in anxiety and depression in univariate analysis, was observed, but was lost after multivariate analysis.

Keywords: Beck depression inventory; SteatoTest; anxiety; cardiovascular disease; depression; hepatic steatosis; metabolic-dysfunction-associated fatty liver disease (MAFLD).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of included and excluded participants.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., Wai-Sun Wong V., Yilmaz Y., George J., Fan J., et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69:2672–2682. doi: 10.1002/hep.30251. - DOI - PubMed
    1. Maurice J., Manousou P. Non-alcoholic fatty liver disease. Clin. Med. 2018;18:245–250. doi: 10.7861/clinmedicine.18-3-245. - DOI - PMC - PubMed
    1. Dumitrascu D.L., Neuman M.G. Non-alcoholic fatty liver disease: An update on diagnosis. Clujul Med. 2018;91:147–150. doi: 10.15386/cjmed-993. - DOI - PMC - PubMed
    1. Sporea I., Popescu A., Dumitrașcu D., Brisc C., Nedelcu L., Trifan A., Gheorghe L., Fierbințeanu Braticevici C. Nonalcoholic Fatty Liver Disease: Status Quo. J. Gastrointestin. Liver Dis. 2018;27:439–448. doi: 10.15403/jgld.2014.1121.274.quo. - DOI - PubMed
    1. Kim D., Konyn P., Sandhu K.K., Dennis B.B., Cheung A.C., Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J. Hepatol. 2021;75:1284–1291. doi: 10.1016/j.jhep.2021.07.035. - DOI - PubMed

LinkOut - more resources